Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on EquityReturn on Sales

BioScience Health Innovations (BHIC) Debt to Equity (2019 - 2022)

BioScience Health Innovations (BHIC) has disclosed Debt to Equity for 4 consecutive years, with $0.38 as the latest value for Q2 2022.

  • Quarterly Debt to Equity rose 119.64% to $0.38 in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $0.38 through May 2022, up 119.64% year-over-year, with the annual reading at -$1.36 for FY2021, 1248.78% down from the prior year.
  • Debt to Equity for Q2 2022 was $0.38 at BioScience Health Innovations, up from $0.05 in the prior quarter.
  • The five-year high for Debt to Equity was $3.22 in Q4 2019, with the low at -$239.04 in Q1 2020.
  • Average Debt to Equity over 4 years is -$21.77, with a median of $0.05 recorded in 2022.
  • The sharpest move saw Debt to Equity crashed 1248.78% in 2021, then surged 119.64% in 2022.
  • Over 4 years, Debt to Equity stood at $3.22 in 2019, then crashed by 39.48% to $1.95 in 2020, then crashed by 91.85% to $0.16 in 2021, then skyrocketed by 136.46% to $0.38 in 2022.
  • According to Business Quant data, Debt to Equity over the past three periods came in at $0.38, $0.05, and $0.16 for Q2 2022, Q1 2022, and Q4 2021 respectively.